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Abstract
Purpose Interleukin 32 (IL-32) is a pro-inflammatory cytokine of which different isoforms have been identified. Recently, IL-32
has been shown to act as a potent inducer of cell migration in several types of cancer. Although previous research showed that IL-
32 is expressed in differentiated thyroid cancer (TC) cells, the role of IL-32 in TC cell migration has not been investigated.
Furthermore, tumour-associated macrophages (TAMs) may play a facilitating role in cancer cell migration. The aim of this study
was to explore whether the interaction between TC cells and TAMs results in increased expression of IL-32 in TC cells and to
investigate whether this affects TC cell migration.
Methods TPC-1 cells were co-culture with TC-induced or naive macrophages. Next, transcriptome analysis on TPC-1 cells was
performed and supernatants were used for stimulation of TPC-1 cells. IL-32β and IL-32γ were exogenously overexpressed in
TPC-1 cells using transient transfection, after which an in vitro gap closure assay was performed to assess cell migration, and the
expression of migratory factors was assessed using RT-qPCR.
Results We found that TC-induced macrophages induced IL-32 expression in TC cells and that TAM-derived TNFα was the
main inducer of IL-32β expression in TC cells. Overexpression of IL-32β and IL-32γ did not affect TC cell migration, but
increased cell death. Finally, we found that IL-32β overexpression led to increased mRNA expression of the pro-survival
cytokine IL-8, while the expression of other migratory factors was not affected.
Conclusions From our data, we conclude that TAM-derived TNFα induces IL-32β in TC cells. Although IL-32β does not affect
TC cell migration, alternative splicing of IL-32 towards the IL-32β isoform may be beneficial for TC cell survival through
induction of the pro-survival cytokine IL-8.
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Abbreviations
EMT Epithelial-to-mesenchymal-transition
GFP Green fluorescent protein
IL-32 Interleukin 32
MMP Matrix metalloproteinase
PBMCs Peripheral blood mononuclear cells
SNP Single nucleotide polymorphism
TAMs Tumour associated macrophages
TC Non-medullary thyroid cancer
TME Tumour microenvironment
TNFα Tumour necrosis factor α
VEGF Vascular endothelial growth factor
1 Introduction
Interleukin 32 (IL-32) is a pro-inflammatory cytokine
that has first been described in 2005 [1]. Since its dis-
covery, nine different isoforms of IL-32 have been iden-
tified, all resulting from alternative splicing of IL-32γ
pre-mRNA [2, 3]. IL-32 has been linked to the patho-
genesis of several diseases, including inflammatory dis-
eases, cardiovascular diseases and cancer [3–9].
Especially in the context of cancer, the role of IL-32
seems ambiguous. Several reports point towards a tu-
mour suppressive role for IL-32 [9–12], with IL-32β
and IL-32γ being associated with inhibition of melano-
ma and colon cancer cell growth [10] and with induc-
tion of an antitumour immune response in prostate and
colon cancer cells [12]. In contrast, other reports indi-
cated that IL-32 may have a more pro-tumorigenic func-
tion, especially with respect to mediating invasion and
migration in lung, breast and gastric cancers and in
osteosarcoma, effects that have not been linked to a
specific isoform [13–16]. Thus, IL-32 seems to exert
opposite effects in the context of different cell- and
cancer types, which also depends on which isoform is
present [9].
The role of IL-32 in non-medullary, differentiated thyroid
cancer (TC) has only scarcely been investigated. Previously,
we have shown that IL-32 protein is expressed in TC, and
mRNA expression analyses showed that both the IL-32β
and IL-32γ isoforms were present in TC tissues [17].
Furthermore, a single nucleotide polymorphism (SNP) in the
promoter of IL-32, resulting in increased IL-32γ production in
immune cells, has been found to be associated with an in-
creased risk of developing TC [17] and an increased resistance
to conventional therapy. Moreover, it has been found that IL-
32β and IL-32γ expression can lead to the induction of
caspase-8 dependent cell death in two different TC cell lines
(FTC-133, follicular PTEN-deficient TC; and BCPAP, papil-
lary BRAF V600E mutated TC) [18].
Previous research suggests that IL-32 may act as a potent
inducer of cell migration in other cancers [13–16], but the effect
of IL-32 expression on TC cell migration and metastasis has
not been investigated. The process of metastasis is complex and
involves several components of the tumour microenvironment
(TME), including pluripotent tumour-associated macrophages
(TAMs), whichmay play a facilitating role. The TME of poorly
differentiated TCs is highly infiltrated with TAMs and this
infiltration has been found to be correlated with a poor prog-
nosis [19, 20]. The mechanisms through which IL-32 is pro-
duced in TCs are not known, and knowledge of the effects of
IL-32 on pro-carcinogenic processes is lacking. TAMs secrete
high amounts of cytokines such as TNFα in response to inter-
actions with TC cells [21], and TNFα has been shown to be
one of the main inducers of IL-32 [1, 3, 4]. We thus hypothe-
sized that IL-32 expression in TC cells may increase in re-
sponse to the presence of activated immune cells, i.e., TAMs,
in the TME. This may, in turn, result in an increased IL-32
mediatedmigration of the tumour cells, potentially contributing
to the metastatic process. Therefore, the aim of the present
study was to explore whether the interaction between TC cells
and innate immune cells induces increased expression of IL-32
in TC cells, and to investigate whether this affects TC cell
migration and/or death in differentiated TCs.
To test this hypothesis, we first assessed the effect of the
interaction between TAMs and TC cells in an in vitro co-
culture model of human monocytes and a TC-derived cell line
(TPC-1). To further assess the effect of IL-32 on TC cell
migration, TC cells were transfected with IL-32β and IL-
32γ after which cell migration in an in vitro gap closure assay
and mRNA expression of migratory factors known to be as-
sociated with IL-32 expression were analysed. These included
IL-8, matrix metalloproteinases (MMPs), the epithelial-to-
mesenchymal transition (EMT) marker E-cadherin and vascu-
lar endothelial growth factor (VEGF) [13–16].
2 Materials and methods
2.1 Co-culture model of the TC cell line TPC-1
and human monocytes
The co-culture in vitro experiments were performed using
TPC-1 cells (papillary, RET/ PTC rearrangement) [22].
TPC-1 cells were grown in RPMI-1640 culture medium,
Dutch modification (Life Technologies, Carlsbad, CA, USA)
supplemented with gentamycin 50 μg/ml, pyruvate 1 mM,
GlutamMAX 2 mM and 10% Fetal Calf Serum (FCS,
Gibco, Life Technologies). Peripheral blood mononuclear
cells (PBMCs) were isolated by density gradient centrifuga-
tion using Ficoll-plaque (GE Healthcare, Diegem Belgium)
from buffy coats obtained from Sanquin Bloodbank,
Nijmegen, The Netherlands. Ethical approval was provided
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by CMO Arnhem-Nijmegen (CMO 2010–104) and all exper-
iments were performed in accordance with the principles
expressed in the Declaration of Helsinki. For transcriptome
analysis, an additional step of purification using CD14-
labelled magnetic beads was performed after PBMC isolation
in order to obtain a highly purified monocyte population.
A trans-well system with ThinCert™ cell culture inserts in
a 24-well plate (Greiner Bio-One GmbH, Austria) was used
for co-culture of TC cells and human monocytes. Cell counts
were performed using a Coulter particle counter (Beckman
Coulter Inc. Pasadena, CA, USA). A total of 1.0 × 105 TPC-
1 cells in 250 μl culture medium was added to the upper
compartments of the trans-well system. Upper compartments
solely with medium were used as negative controls. Culture
medium was added to the lower compartments and the cells
were incubated for 24 h at 37 °C, 5% CO2. Next, the cells
were washed with phosphate buffered saline (PBS, Braun
Melsungen, Germany) after which fresh co-culture medium,
containing a physiological concentration of glucose, was
added: RPMI-1640 without glucose (Life Technologies,
Carlsbad, California, USA) supplemented with glucose
5 mM, pyruvate 1 mM, gentamicin 50 μg/ml and HEPES
10 mM (Life Technologies, Carlsbad, California, USA).
Monocytes were isolated as described above and resus-
pended in the co-culture medium. A total of 5.0 × 105 mono-
cytes in 500 μl was added to the lower compartments of the
trans-well system. After adhesion for 1 h in the 24-well plates,
the non-adherent cells were discarded, and the adherentmono-
cytes were incubated further with TPC-1 cells or medium
alone for 24 h at 37 °C in co-culture medium. After 24 h
incubation, the adherent monocytes, now called naïve mono-
cytes or TC-induced macrophages, respectively, were stimu-
lated for 24 h with RPMI-1640 or 10 ng/ml LPS (E. coli strain
O55:B5, Sigma Chemical Co, St. Louis, MO, USA) as sub-
stitute for endogenous TLR4 ligand signalling, while leaving
the trans-wells containing medium or TPC-1 cells in place. At
the end of the incubation period, TPC-1 cells were lysed in
200 μl Trizol reagent (Invitrogen, Carlsbad, CA, USA) and
stored at −80 °C for transcriptome analysis. Supernatants
where collected and stored at −80 °C for subsequent condi-
tioned medium experiments. A schematic representation of
the experimental set-up is provided in Supplementary Fig. S1.
2.2 RNA sequencing of TPC-1 cells co-cultured
with monocytes
RNA isolation was performed according to the Trizol manu-
facturer’s instructions (Invitrogen, Carlsbad, CA, USA). 50 ng
RNA was converted into cDNA libraries according to the
TruSeq RNA library preparation kit v2. After cluster genera-
tion on a cBot (Illumina), a 75 bp single read (SR) rapid run
was performed on an Illumina HiSeq 1500 system.
2.3 RNA-Seq pre-processing and statistical analysis
of samples
After base calling and de-multiplexing using CASAVA ver-
sion 1.8, the 75 bp single-end reads were aligned to the human
reference transcriptome hg38 from UCSC by kallisto v0.44.0
using default parameters. Data were imported into DESeq2
(v.1.10.1) using the TXimport (v1.2.0) package. DESeq2
was used for the calculation of normalized counts for each
transcript using default parameters. After DESeq2 normaliza-
tion, all normalized transcripts with a maximum over all group
means lower than 10 were excluded resulting in 17,099 pres-
ent genes. Unwanted or hidden sources of variation, such as
batch and preparation date, were removed using the sva pack-
age [23]. The normalized rlog transformed expression values
were adjusted according to the two surrogate variables identi-
fied by sva using the function removeBatchEffect from the
limma package [24]. Differentially expressed (DE) genes
were defined by a |fold change| > 1.5 and an adjusted p value
(FDR) < 0.05. Log2 fold changes were plotted against –log10
adjusted p values in a volcano plot. Top 10 up- and down-
regulated genes were marked in the volcano plot. Sashimi
plots were generated by visualizing the aligned reads using
the Integrative Genome Viewer (IGV) [25], and the function
sashimi plot. Principal component analysis was performed on
all present genes. Detailed data have been deposited in the
GEO database with accession number GSE120391.
2.4 Stimulation of TC cell lines with conditioned
medium and TNFα
To test whether induction of IL-32 mRNA expression in TPC-
1 was caused by paracrine factors from the co-culture medi-
um, fresh TPC-1 cells were stimulated with supernatants from
TPC-1-monocyte co-culture experiments for 24 h. Since
TNFα is an important inducer of IL-32 [1, 4] and TNFα is
abundantly present in the co-culturemedium [21], TPC-1 cells
were also stimulated with TNFα (100 ng/ml R&D Systems,
Minneapolis, MN, USA) for 24 h. Briefly, 500.000 cells/well
were seeded in a 24-well plate (Corning, NewYork, USA) and
left to adhere for 18 H. Medium was replaced with fresh me-
dium mixed with supernatants from co-culture experiments in
a 1:1 ratio or fresh medium with TNFα (100 ng/ml). To test
whether IL-32 could also be induced in other TC cell lines,
two additional cell lines were included, i.e., BC-PAP (papil-
lary TC, BRAF V600E mutation) and FTC-133 (follicular
TC, PTEN deficient) [22]. To confirm the role of TNFα, spe-
cific TNFα inhibitors, etanercept (decoy receptor, 10 μg/ml,
Enbrel©, Pfizer, New York, USA) and adalimumab (mono-
clonal antibody, 10 μg/m, Humira©, Abbott GmbH & Co.
Wiesbaden, Germany) were added to pre-selected
experiments.
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2.5 Expression vectors and transient transfection
of TPC-1 cells
pcDNA3-based vectors for the expression of IL-32β and
IL-32γmutant were generated by standard PCR and re-
striction based cloning methods. The expression plas-
mids were constructed with a Kozak sequence (5′-
GCCGCCACC-3′) immediately upstream of the ATG
start codon followed by full-length cDNAs of human
IL-32β, IL-32γ and eGFP or an empty DNA (control).
An IL-32γmutant was created that cannot be spliced into
other IL-32 isoforms like regular IL-32γ, to investigate
the effect of IL-32γ without the effect of over-
expression of other IL-32 splice variants. The IL-
32γmutant was created by mutation of a donor splice site
from GU to AU as described previously [2].
TPC-1 cells were transfected with pCDNA3 plasmids
expressing IL-32β, IL-32γmutant or empty DNA, togeth-
er with pCDNA3 plasmids expressing eGFP in a 10:1
ratio. Briefly, cells were seeded at a density of approx-
imately 40.000 cells per cm2 in a 10 mm dish (VWR,
Radnor, PA, USA). Medium was refreshed after 24 h
and cells were transfected using Fugene (Promega
Corporation, Madison, WI, USA) according to the man-
ufacturers’ protocol. After 24 h, cells were collected
using trypsin/EDTA (Life Technologies), counted using
a Bürker-Türk counter chamber (Sigma Aldrich Chemie,
Zwijndrecht, The Netherlands) and Tryphan blue stain-
ing (Sigma), and only live cells were reseeded for fur-
ther experiments.
2.6 Transfection efficiency and Ki-67 staining
To quantify the transfection efficiency, 200.000 cells were
reseeded after transfection. After 40 h and 64 h, the cells were
trypsinised, centrifugated and fixed through resuspension in
Fix and Perm buffer (Life technologies) for 45min. After wash-
ing in Perm buffer, the cells were stained with an anti-Ki-67
monoclonal antibody (SolA15, invitrogen, Carlsbad, CA,
USA) as a marker for proliferation activity, and incubated for
30 min in the dark at 4 °C. Next, the cells were washed and
resuspended in PBS containing 1% Bovine Serum Albumin
(BSA , S i gm a -A l d r i c h Ch em i e , Zw i j n d r e c h t ,
The Netherlands) for analysis by flow cytometry. A Cytoflex
flow cytometer (3 lasers, Beckman Coulter Inc.) was used to
determine the percentage of transfected cells (i.e., GFP express-
ing cells) by setting the excitation at 488 nm, the emission at
525 nm (FITC channel) and recording 100.000 events per sam-
ple. The percentage of Ki-67 positive cells was determined by
setting the excitation at 488 nm and the emission at 610 nm
(ECD-A channel). The percentage of positive cells was obtain-
ed using a fluorescence intensity histogram, which represents
the number of events at a given fluorescence intensity.
2.7 Cytotoxicity assay
To assess cytotoxicity, we performed a Cytotox96 assay
(Promega, Madison, WI, USA) according to the manufac-
turer’s protocol.
2.8 Western blotting
To assess IL-32 protein expression, cells were seeded at a den-
sity of 300.000 cells/well in a 24-well plate (Corning). At two
different time points, 40 and 64 h after transfection, cells were
lysed in lysis buffer containing phosphatase and protease inhib-
itors (Roche, Basel, Switzerland) after which proteins were
loaded on a pre-casted 4–15% gel (Biorad, CA, USA) for poly-
acrylamide gel electrophoresis. The separated proteins were
transferred to a nitrocellulose membrane (Biorad) after which
incubation overnight at room temperature with a goat-anti-IL-
32 (AF3040) antibody (R&D systems, Minneapolis,
Minnesota, USA) was used to detect IL-32 protein. Detection
of actin with a rabbit anti-actin antibody (Sigma) was used to
verify protein concentrations. Polyclonal secondary antibodies
(Dako, Begium) and a Clarity Western ECL Blotting Substrate
(Biorad) were used to visualize protein expression.
2.9 RNA isolation, cDNA synthesis and RT-qPCR
For mRNA expression analyses, TPC-1 cells (200.000/well)
were lysed in TRIzol reagent (Invitrogen, Carlsbad, CA,
USA) and stored at −80 °C. RNA isolation was performed
according to the manufacturer’s instructions and transcribed
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Fig. 1, F, first panel: IL-32α Co-culture of TPC-1 cells with TC-
induced monocytes induces IL-32 expression. (a) Bioinformatics data
analysis workflow of transcriptomic changes induced in TPC-1 cells co-
cultured with TC-induced monocytes (4 monocyte donors) and re-
stimulation with RPMI-1640 (medium control) or LPS (TLR-4 ligand).
QC/QA = quality control/quality assurance. (b) PCA of the transcriptome
data, showing the group relationships of TPC-1 cells co-cultured with
TC-induced monocytes after re-stimulation with RPMI-1640 (RPMI) or
LPS (LPS). The proportion of component variance is indicated as a per-
centage. (c) Bar graph showing the number of differentially expressed
transcripts with fold change of 1.5 (log2 fold change of 0.58) and adjusted
p value < 0.05. (d) Volcano plot of the transcriptional changes of TPC-1
cells co-cultured with TC-induced monocytes after re-stimulation with
RPMI-1640 (RPMI) or LPS (LPS). The X-axis specifies the log2 fold-
changes (FC) and the Y-axis specifies the p-values as the negative loga-
rithm to the base 10 of the t-test. Red and blue dots represent transcripts
expressed at significantly higher (n = 98) or lower (n = 30) levels after
LPS re-stimulation. (e) Sashimi plots quantitatively visualizing the splice
junctions for TPC-1 cells co-cultured with TC-induced monocytes after
re-stimulation with RPMI-1640 (RPMI) or LPS (LPS) based on their
alignment to the reference genome. (f) Stimulation of TPC-1 cells with
supernatants from TC-induced monocytes (n = 8), naive monocytes
(n = 8) and TPC-1 cells alone (n = 4) after re-stimulation with RPMI-
1640 (medium control) or LPS (TLR-4 ligand). Results from 4 experi-
ments, using 2 separate monocyte-donors per experiment. Data are rep-
resented as mean ± SEM; * p < 0.05, by Wilcoxon matched-pairs signed
rank test
into cDNA by reverse transcription using an iScript cDNA
Synthesis Kit (Bio-Rad). A Power SYBR Green PCR Master
Mix (Applied Biosystems, CA, USA) was used for RT-qPCR
in a CFX384 Touch Real-Time PCR Detection System (Bio-
Rad). Expression data were normalized to the housekeeping
genes human β2M or GAPDH. The primers used were pur-
chased from Biolegio (Nijmegen, The Netherlands) and the
sequences used for RT-qPCR are listed in Supplementary
Table S1. In the different stimulation experiments the mRNA
expression levels of IL-32 isoforms α, β and γ were assessed.
After transfection, the mRNA expression levels of migratory
factors associated with IL-32 expression were assessed, includ-
ing IL-8, MMP2, 3 and 9, the EMT-marker E-cadherin and
VEGF [13–16]. The mRNA expression level of IL-32α was
also assessed, as this is an IL-32 splicing product and expres-
sion of IL‐32β and IL‐32γ could, therefore, also result in an
increased IL‐32α mRNA level.
2.10 Gap closure assay
In vitro gap closure assays were conducted using silicone cell
culture inserts (Ibidi GmbH, Martinsried Germany) attached
to culture plates. TPC-1 cells were seeded into the inserts
(28.000 cells/insert chamber) and left to adhere overnight to
form a confluent monolayer. Next, the inserts were removed
with tweezers, and the cells were rinsed with PBS once to
remove detached cells. Normal RPMI-1640 culture medium
containing either 0% or 10% FCS was added after which gap
closure was assessed at different time points using conven-
tional light microscopy. Gap closure was quantified by
ImageJ, using the MRI wound healing tool (National
Institute of Health, Bethesda, MD, USA).
2.11 Statistical analysis
All analyses were performed in Graphpad prism 5 (CA, USA).
Differences in mRNA expression levels, GFP and Ki-67 pos-
itivity, cytotoxicity and differences in gap closure, were
analysed using Kraskal Wallis test with Dunnets multiple
comparison test, or Mann Whitney test to compare different
conditions to control condition, or paired Wilcoxon signed
rank test to compare effects within conditions. * p < 0.05, **
p < 0.01. Data are shown as means ± SEM.
3 Results
3.1 Co-culture of TPC-1 cells and monocytes leads
to increased IL-32α and IL-32βmRNA expression in TC
cells
To investigate transcriptional differences of TPC-1 cells after co-
culture with inactivated (control, RPMI-1640 stimulated) or
TLR-4 activated (LPS stimulated) TC-induced-macrophages
on a global level, we generated genome-wide transcriptome data
through quantitative RNA-sequencing in TPC-1 cells and per-
formed bioinformatic analyses (Fig. 1a). Unbiased principle
component analysis (PCA) based on 17,099 transcripts (Fig.
1b) revealed significant transcriptional changes in TPC-1 cells
after co-culturewith TLR-4 activated TC-inducedmacrophages.
Differential gene expression analysis (FC ≥ 1.5) revealed 98
significantly upregulated and 30 significantly downregulated
genes (Fig. 1c). Indeed, IL-32was among the top 10 upregulated
genes as visualized by Volcano Plot (Fig. 1d). Sashimi plots
(Fig. 1e) show the splice junctions for TPC-1 cells co-cultured
with TC-induced macrophages after re-stimulation with RPMI-
1640 (control) or TLR-4 ligand (LPS), indicating that IL-32β is
the most probable splice variant.
Next, we found that stimulation of TPC-1 cells with super-
natants from TC-induced macrophages, naive monocytes and
TPC-1 cells only, confirmed that paracrine factors from acti-
vated TC-induced macrophages induced IL-32 expression in
TPC-1 cells (Fig. 1f). We also found that supernatants from
TLR-4 stimulated TC-induced macrophages induced signifi-
cantly higher IL-32α, IL-32β and IL-32γ mRNA expression
levels in TPC-1 cells (p = 0.0156) compared to supernatants
from RPMI stimulated TC-induced macrophages.
Supernatants from TLR-4 stimulated TC-induced macro-
phages were found to induce in the highest levels of IL-32β,
with a fold change of 16.77 ± 6.17 compared to 9.23 ± 5.55 in
naive, TLR-4 stimulated monocytes (p = 0.0313).
3.2 TNFα is a strong inducer of IL-32β in TC cells
We have previously shown that TC-induced macrophages
produce increased levels of TNFα and IL-6 compared to naive
monocytes [21]. Since TNFα is one of the main inducers of
IL-32, we hypothesized that the high levels of TNFα in the co-
culture supernatants might be responsible for the rise in IL-32
mRNA expression in TC. To test this hypothesis, TPC-1 cells
were stimulated with TNFα (100 ng/ml), after which again
increased mRNA expression levels of IL-32α (p = 0.0079)
and IL-32β (p = 0.0079) were observed, whereas the IL-32γ
expression level was not significantly altered (Fig. 2a). To
investigate whether TNFα could also induce IL-32 in other
TC-derived cell lines, BC-PAP (papillary TC, BRAF V600E
mutation) and FTC-133 (follicular TC, PTEN deficient) cells
were stimulated with TNFα as well. In both BC-PAP and
FTC-133 cells the IL-32α and IL-32β mRNA expression
levels were found to be upregulated after stimulation with
TNFα, albeit to a lesser extent (Fig. 2a).
Using Western-blot analysis, we confirmed that TNFα in-
duced IL-32 expression at the protein level in all three TC-
derived cell lines (Fig. 2b). The highest level was found in
TPC-1 cells, most likely being IL-32β as based on protein size
(25.9 kDa, Supplementary Fig. S2A).We found that the use of
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Fig. 2 TNFα-mediated IL-32 mRNA and protein expression in dif-
ferent TC cell lines. (a) Relative mRNA expression of IL-32α, IL-32β
and IL-32γ isoforms in 3 different TC cell lines, TPC-1 (RET/PTC rear-
rangement), FTC-133 (PTEN-deficient) and BC-PAP (BRAF V600E
mutation) after stimulation with RPMI-1640 (medium control) or
TNFα (100 ng/ml). Results from 3 to 5 experiments, including 1–3 rep-
licates. (b) Western blot analysis showing IL-32 protein expression after
stimulation with TNFα in TPC-1, FTC-133 and BC-PAP cells. (c)
Relative mRNA expression levels of IL-32α, IL-32β and IL-32γ
isoforms in TPC-1 cells after stimulation with TNFα and in the presence
of Enbrel (etanercept, decoy TNFα-receptor, 10 μg/ml) or Humira
(adalimumab, monoclonal TNFα antibody, 10 μg/ml). Results from 3
to 5 experiments, including 1–3 replicates. (d) Western blot analysis
showing IL-32 protein expression in TPC-1 cells after stimulation with
TNFα and in the presence of Enbrel or Humira. Data are presented as
mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001 byMann-Whitney-U
test or Kruskal Wallis test with Dunn’s multiple comparison test
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two different inhibitors of TNFα, Humira and Enbrel, abro-
gated the upregulation of IL-32 in the TC cell lines, further
confirming that TNFα acts as an important inducer of IL-32β
mRNA and protein expression in TC (Fig. 2c, d and
Supplementary Fig. S2B-D).
3.3 IL-32 overexpression results in increased
cytotoxicity without affecting Ki-67 in TC cells
Since IL-32 mRNA and protein expression was highest in
TPC-1 cells, we next exogenously overexpressed IL-32β
and IL-32γ in TPC-1 cells. IL-32β was used because this
isoform was most highly expressed in TC. Since IL-32γ is
known as most potent isoform of IL-32 for several functions
[3], IL-32γ was also included in these experiments. To inves-
tigate the effect of IL-32γwithout the effect of overexpression
of other IL-32 splice variants, an IL-32γmutant vector was cre-
ated, which cannot be spliced into other IL-32 isoforms like
regular IL-32γ. The transfection efficacy was assessed by cal-
culating the percentage of green fluorescent protein (GFP)-
positive cells at two different time points [t = 40 h (start of
gap closure assay), and t = 64 h, (end of gap closure assay)].
We found that the mean percentage of GFP-positive cells at
40 h after transfection in serum-rich conditions (10%FCS) did
not differ significantly, and was lowest in the control
transfected cells (46.2 ± 14.1%) and highest in the IL-
32γmutant transfected cells (74.0 ± 9.2%) (Fig. 3a). Sixty-four
hours after transfection, the mean percentage of GFP-positive
cells was only slightly increased (not significant) in both
serum-rich (10% FCS) and serum-deprived (0% FCS) condi-
tions. In addition, we found that transfection with either IL-
32β or IL-32γmutant resulted in high levels of protein expres-
sion of the indicated IL-32 isoform in TPC-1 cells at both time
points (Fig. 3b, t = 40 h; data for t = 64 h not shown), while
control transfected cells (empty vector) showed no IL-32 pro-
tein expression. Interestingly, we detected both IL-32β and
IL-32γ protein in the 32γmutant transfected cells.
Next, the effect of exogenous IL-32 overexpression on cy-
totoxicity was assessed. An increased cytotoxicity was ob-
served at 40 h after transfection for all conditions compared
to non-transfected cells (p = 0.0006) (Fig. 3c), indicating that
transfection did result in increased cell death. At 64 h post
transfection, we found lower percentages of cytotoxicity due
to transfection, and that both IL-32β and IL-32γ overexpres-
sion induced significantly more cytotoxicity both in the pres-
ence of serum (p = 0.0043 and p = 0.0022) and in the absence
of serum (p = 0.0411 and p = 0.0129). IL-32γ overexpression
resulted in the highest level of cell death in the presence of
serum (25.5 ± 3.3% cytotoxicity for IL-32γ transfected cells
compared to 18.4 ± 0.5% in control transfected cells).
To investigate the effect of IL-32 on proliferation, we ana-
lyzed whether the expression of Ki-67, a marker for prolifer-
ation, was affected by exogenous IL‐32 overexpression. We
found that > 98% of all cells were Ki‐67 positive in all con-
ditions, and that all GFP-positive cells were also Ki-67 posi-
tive (Fig. 3d). The mean fluorescence intensity of Ki-67 stain-
ing in IL-32γmutant transfected cells was found to be lower
compared to that in control transfected cells and IL-32β
transfected cells, but the differences were not statistically sig-
nificant (Fig. 3e, f). Thus, we conclude that IL-32 overexpres-
sion did not affect the percentage of Ki-67-positive cells and
only slightly affected Ki-67 intensity.
3.4 IL-32 overexpression does not affect TC cell
migration
Next, the effect of exogenous IL-32β and IL-32γ overexpres-
sion on TC cell migration in an in vitro gap closure assay was
assessed (see example in Fig. 4a). Figure 4b shows the per-
centage of the gap that the cells filled in a 24 h period. As
expected, we found the highest percentage of gap closure in
serum-rich conditions with an abundance of growth and mi-
gratory factors. When comparing control transfected cells
with IL-32β or IL-32γ transfected cells, no significant differ-
ences were found in the percentages of gap closure after 24 h,
neither in serum-deprived nor in serum-rich conditions.
Finally, we assessed the mRNA expression levels of factors
known to be associatedwith IL-32 expression and cellmigration
in serum rich conditions. At 64 h after transfection, we found
that the mRNA expression levels of IL-32α, IL-8 and VEGF
were significantly reduced in all conditions compared to those
40 h after transfection (Fig. 5). The IL-32α and IL-8 mRNA
expression levels were significantly upregulated in IL-32β-
transfected cells at 64 h after transfection compared to those in
control transfected cells (p = 0.0003 and p = 0.0120). The IL-
32αmRNA expression level was also significantly higher after
40 h in both IL-32β- and IL-32γ-transfected cells compared to
control transfected cells. IL-32β and IL-32γ overexpression did
not result in any significant differences in mRNA expression
Transfection efficiency determined by GPF positivity using flow
cytometry at 40 h and 64 h post-transfection. Results from 3
experiments. (b) Western blot analysis showing overexpression of IL-
32β and IL-32γ protein in TPC-1 cells 40 h after transfection, while
control transfected cells (empty) show no IL-32 protein expression. (c)
Cytotoxicity measured at 40 h (10% FCS, n = 4) and 64 h post-
transfection (0% and 10% FCS, n = 3) in non-transfected cells, control
transfected cells (empty) and IL-32β and IL-32γmutant transfected cells.
Results from 3 to 4 experiments, 1–3 replicates per experiment. (d)
Expression of Ki-67 proliferation marker in transfected TPC-1 cells using
flow cytometry. White portion of the bar indicates GFP and Ki67 positive
cells, grey portion of the bar indicates Ki67-only positive cells and black
portion of the bar indicates unstained cells. (e-f) Mean fluorescence
Intensity (MFI) of Ki-67 staining 40 h after transfection. Results from 3
experiments. Data are presented as mean ± SEM; * p < 0.05, ** p < 0.01,
*** p < 0.001 by Mann-Whitney-U test or Kruskal Wallis test with
Dunn’s multiple comparison test
Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid... 699
Fig. 3 Overexpression of IL-32β and IL-32γ in TPC-1 cells. (a)
levels of MMP2, 3 or 9, E-cadherin or VEGF compared to
control transfected cells at both time points.
4 Discussion
In the present study, we show that IL-32 mRNA and protein
expression in TC is strongly upregulated by TNFα derived from
TC-induced macrophages, with IL-32β being the predominant
isoform expressed by TC cells. Overexpression of IL-32β and
IL-32γ in TC cells resulted in an increased cytotoxicity, without
significantly affecting the expression of the proliferation marker
Ki-67. Interestingly, we found that exogenous IL-32β overex-
pression in TC cells resulted in increased IL-8 mRNA expres-
sion, while other markers associated with cancer cell migration
were not affected by either IL-32β or IL-32γ overexpression.
Lastly, we found that exogenous IL-32β and IL-32γ overexpres-
sion did not affect TC cell migration in an in vitro model system.
An important finding was that IL-32 expression becomes
highly upregulated in TC cells after co-culture with TLR-4-
activated TC-induced macrophages. Especially the isoform
IL-32β was found to be strongly induced after stimulation of
TC cells with supernatants from activated TC-induced macro-
phages. Since TNFα is abundantly present in supernatants from
activated TC-induced monocytes [21] and TNFα stimulation of
TC cells results in the same pattern of induction of mainly IL-
32β, it is reasonable to assume that TNFα is the main paracrine
factor responsible for the induction of IL-32β in TC cells.
Interestingly, although TNFα has been shown to be a potent
inducer of IL-32γ in human synovial fibroblasts [4], our results
show that TNFαmainly induces IL-32β in TC cells and could,
therefore, be considered an inducer of alternative splicing of IL-
32 in TC. IL-32γ is considered to be the most potent isoform of
IL-32 [3] and blocking of alternative splicing, resulting in pre-
dominantly IL-32γ expression, has been shown to induce cell
death in FTC-133 and BCPAP TC cells [18]. In the present
study, we have demonstrated that exogenous overexpression
of IL-32γ significantly increased cytotoxicity in TPC-1 cells
as well. These results indicate that IL-32γmay potently induce
cell death in TC cells. Induction of alternative splicing by
TNFα deduced from TC-induced macrophages, resulting in
increased levels of IL-32β and IL-32α and reduced levels of
IL-32γ, could protect TC cells from cell death. We found that
IL-32β overexpression in TPC-1 cells resulted in slightly less
cell death, and a significant increase in IL-8 mRNA expression,
whereas IL-32γ did not. IL-8 is an important pro-survival cy-
tokine [26] and restoring the IL-8 signalling pathway has been
found to rescue IL-32β-induced cell death in HEK293 cells
[18]. Our results further showed that the expression of Ki-67,
an important marker of proliferation, was slightly reduced after
exogenous IL-32γ overexpression, suggesting a reduced pro-
liferation potential. These results support the hypothesis that
stimulation of alternative splicing towards IL-32βmay be ben-
eficial for TC cells in terms of survival.
Exogenous IL-32β and IL-32γ overexpression in TPC-1
cells resulted in a high protein expression of the indicated iso-
forms. However, exogenous IL-32γmutant overexpression also
resulted in IL-32β protein expression. This is surprising, since
the IL-32γmutant pre-mRNA cannot be spliced. It is, therefore,
likely that IL-32γmutant protein overexpression can induce the
transcription of endogenous IL-32 mRNA in the transfected
TCP-1 cells [2], which may result in increased levels of IL-
32βmRNA as well, as evidenced by increased IL-32β protein
expression at the later time point. In line with these findings, we
observed lower levels of IL-32α mRNA in IL-32γmutant
transfected cells compared to that in IL-32β transfected cells.
In contrast to what we hypothesized, we found that IL-32β
and IL-32γ overexpression did not affect in vitro TC cell mi-
gration. Factors that have previously been found to be important
Fig. 4 Overexpression of IL-32β and IL-32γ in TPC-1 cells does not
affect gap closure. (a) The effect of IL-32β and IL-32γ overexpression
on TC cell migration was assessed in a gap closure assay using IBIDI©
inserts to create a cell-free zone. Gap closure was assessed after 24 h using
the MRI wound healing tool in ImageJ. (b) The effect of IL-32β (n = 5)
and IL-32γ (n = 3) overexpression on TC cell migration in serum-
deprived (0% FCS) or serum-rich conditions (10% FCS) depicted as
percentage of the gap that is closed after 24 h. Results from 3 to 5 exper-
iments, 2–3 replicates per experiment. Data are represented as mean ±
SEM; * p < 0.05, by Mann-Whitney-U test
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in IL-32-induced cell migration [13–16], were also not signifi-
cantly affected in TC cells after IL-32β and IL-32γ overexpres-
sion. Interestingly, however, we found that the mRNA
expression levels of IL-8 and VEGF decreased over time, with
significant lower expression levels 64 h after transfection. It is
possible that the TPC-1 cells continued to proliferate, as
Fig. 5 mRNA expression of
migratory factors associated
with IL-32 induced cancer cell
migration. mRNA expression of
IL-32α, IL-8, matrix
metalloproteinases (MMP) 2, 3
and 9, epithelial-to-
mesenchymal-transition (EMT)
marker E-cadherin and vascular
endothelial growth factor (VEGF)
in the presence of 10% FCS.
Results from 3 experiments, 2–3
replicates per experiment. Data
are presented as mean ± SEM; *
p < 0.05, ** p < 0.01, ***
p < 0.001 by Mann-Whitney-U
test or Kruskal Wallis test with
Dunn’s multiple comparison test
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indicated by Ki-67 expression, and became confluent af-
ter 64 h, resulting in contact inhibition, which could lead
to entrance in a resting state and thus a reduced IL-8 and
VEGF expression [27, 28].
In the present study, we only focused on the role of IL-32 in
the interplay between TAMs and differentiated TC cells.
However, TAMs are able to interact with other immune cells
in the tumour micro-environment as well through release of
soluble factors such as chemokines and cytokines (e.g. IL-6
and TNFα) [21]. The pro-inflammatory cytokines produced
by TAMs in TC are known to stimulate adaptive immune
responses. Interestingly, pro-inflammatory cytokines such as
TNFα have also been shown to induce dedifferentiation of
tumours, resulting in adaptive immune resistance [29, 30].
Thus, via an indirect route, TAMs may influence adaptive
anti-tumour immune responses in TC as well. Interestingly,
in the present study we found that TAM-derived TNFα in-
duced IL-32 expression in TC cells and IL-32 expression in
tumour cells is known to affect adaptive immune responses in
several other solid cancers [9]. In vitro studies and animal
models of different solid cancer types, including colon and
prostate cancer, have revealed that IL-32β can stimulate the
adaptive anti-tumour response by inducing NK cytotoxicity,
thereby increasing T cell infiltration and stimulating a cyto-
toxic T cell response [12, 31, 32]. As this was beyond the
scope of our study, future studies are warranted to assess the
effect of IL-32 on adaptive anti-tumour responses in TC.
Although previous work has shown that TAM densities
may be even higher in more advanced cancers, such as poorly
differentiated TC and anaplastic TC [19, 20, 33], little exper-
imental data are available on functional interactions between
TAMs and TC cells in other subtypes of TC. For follicular TC,
we have previously reported that co-culture with a follicular
cancer cell line (FTC-133, PTEN-deficient) induced an even
more proinflammatory phenotype in TC-induced macro-
phages compared to that by a papillary TC cell line (TPC-1,
RET/ PTC rearrangement) [34]. These results indicate that IL-
32β may be more strongly induced in follicular TC, as the
levels of TAM-derived TNFα are also significantly higher
and, thus, could play a more important role in follicular TC.
However, future studies are needed to investigate the function-
al interactions between TAMs and other subtypes of TC, as
well as the effect of IL-32 in other subtypes of TC.
In conclusion, we found that TAM-derived TNFα is
the main inducer of IL-32 alternative splicing in TC
cells, resulting in upregulation of IL-32β expression.
Although IL-32β does not affect TC cell migration, al-
ternative splicing of IL-32 towards IL-32β is likely ben-
eficial for TC cell survival by reducing IL-32γ-induced
cell death and inducing increased levels of the pro-
survival cytokine IL-8. Therefore, modulation of IL-32
alternative splicing could be explored as potential novel
treatment strategy for patients with advanced TC.
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